Primary Hyperoxaluria News Today

Nedosiran (Rivfloza) was approved for children and adults with primary hyperoxaluria type 1 (PH1), according to drugmaker Novo Nordisk.

/PRNewswire/ -- Novo Nordisk announced today that the U.S. Food and Drug Administration (FDA) has approved RivflozaTM (nedosiran) injection 80 mg, 128 mg, or...

The Global Fuchs Endothelial Corneal Dystrophy Market Size was valued at USD 170 Billion in 2022 and the Worldwide Fuchs Endothelial Corneal Dystrophy...

Global Live Biotherapeutic Product (LBP) Market worth $ 2.60 billion by 2030 – InsightAce Analytic

In patients with PH1 and advanced kidney disease, including patients on hemodialysis, use of Lumasiran shows substantial reductions in plasma oxalate levels with acceptable safety.

/PRNewswire/ -- InsightAce Analytic Pvt. Ltd. has announced the publication of a market research report titled "Global Live Biotherapeutic Product (LBP) Market...

JERSEY CITY, N.J., July 7, 2022 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. has announced the publication of a market research report titled "Global Live Biotherapeutic Product (LBP) Market

A 12-year-old boy with rare liver disease underwent a successful multi-organ transplant in Chennais Gleneagles Global Health City (GGHC).

/PRNewswire/ -- OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announces...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Royalty Pharma Acquires OXLUMO™ Royalty Interest From Dicerna for up to $240 Million RP Management, LLCApril 8, 2021 GMT Dicerna to receive $180 million upfront and up to $60 million in potential additional milestone payments NEW YORK and LEXINGTON, Mass., April 08, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) (“Royalty Pharma”) and Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (“...